{"entity":{"id":"lerotinib","kind":"drug","name":"Lerotinib","aka":["Z650"],"tldr":"Lerotinib is an experimental small-molecule drug from Sunshine Lake Pharma in phase 3 trials for oesophageal cancer, with its target not yet stated publicly.","summary":"Lerotinib is a small-molecule drug developed by Sunshine Lake Pharma. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Specification: 50 mg/capsule and 150 mg/capsule. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT04415853 (Study of Larotinib in Unresectable Advanced or Recurrent Oesophageal Cancer), in oesophageal cancer. The largest, NCT04415853, plans to enrol 416 participants with primary completion was scheduled for 2026-08 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Lerotinib","url":"https://clinicaltrials.gov/search?intr=Lerotinib"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04415853"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lerotinib/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"trial":[{"id":"nct04415853","kind":"trial","name":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","route":"/trials/nct04415853/"}],"company":[{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","route":"/companies/sunshine-lake-pharma/"}]}}